Study validates biomarkers for oesophageal cancer blood test
Filed with ASX · · 3 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Proteomics to raise $6.5m through Institutional Placement
- December 2023 Quarterly Activities Report and Appendix 4C
- PromarkerD licence with Omics Global extended to Chile
- US Medicare confirms reimbursement price for PromarkerD
- Proteomics receives $1.85 million in R&D tax incentive
Later from Proteomics International Laboratories
- European patent granted for OxiDx technology
- PromarkerD US commercialisation & Promarker pipeline update
- Proteomics signs with Oxford Univ to validate test for Endo
- March 2024 Quarterly Activities Report and Appendix 4C
- Proteomics appoints medical devices sales agency for Europe
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories